UA61058C2 - Immortalized human fetal neuro-derived cell line intended for treating parkinsonism, composition suitable for implantation containing immortalized cells - Google Patents
Immortalized human fetal neuro-derived cell line intended for treating parkinsonism, composition suitable for implantation containing immortalized cells Download PDFInfo
- Publication number
- UA61058C2 UA61058C2 UA98010030A UA98010030A UA61058C2 UA 61058 C2 UA61058 C2 UA 61058C2 UA 98010030 A UA98010030 A UA 98010030A UA 98010030 A UA98010030 A UA 98010030A UA 61058 C2 UA61058 C2 UA 61058C2
- Authority
- UA
- Ukraine
- Prior art keywords
- cells
- zmo
- cell
- cell line
- immortalized
- Prior art date
Links
- 230000001605 fetal effect Effects 0.000 title claims abstract description 28
- 241000282414 Homo sapiens Species 0.000 title claims abstract description 22
- 208000027089 Parkinsonian disease Diseases 0.000 title claims description 19
- 206010034010 Parkinsonism Diseases 0.000 title claims description 19
- 239000000203 mixture Substances 0.000 title claims description 5
- 238000002513 implantation Methods 0.000 title abstract description 39
- 238000002054 transplantation Methods 0.000 claims description 41
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 40
- 238000011282 treatment Methods 0.000 claims description 24
- 229940076279 serotonin Drugs 0.000 claims description 20
- 150000007523 nucleic acids Chemical class 0.000 claims description 18
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 claims description 17
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 claims description 16
- 239000012528 membrane Substances 0.000 claims description 13
- 108020004707 nucleic acids Proteins 0.000 claims description 13
- 102000039446 nucleic acids Human genes 0.000 claims description 13
- 230000001537 neural effect Effects 0.000 claims description 12
- 229940072056 alginate Drugs 0.000 claims description 4
- 235000010443 alginic acid Nutrition 0.000 claims description 4
- 229920000615 alginic acid Polymers 0.000 claims description 4
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 3
- 238000000034 method Methods 0.000 abstract description 51
- 210000004027 cell Anatomy 0.000 description 379
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 28
- 241001465754 Metazoa Species 0.000 description 26
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 26
- 108090000765 processed proteins & peptides Proteins 0.000 description 26
- 210000003169 central nervous system Anatomy 0.000 description 25
- 210000001519 tissue Anatomy 0.000 description 25
- 201000010099 disease Diseases 0.000 description 23
- 241000282693 Cercopithecidae Species 0.000 description 20
- 210000002569 neuron Anatomy 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- 210000004556 brain Anatomy 0.000 description 16
- 210000003754 fetus Anatomy 0.000 description 14
- 210000001577 neostriatum Anatomy 0.000 description 14
- 241000700159 Rattus Species 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- 229960003638 dopamine Drugs 0.000 description 12
- 108010035004 Prephenate Dehydrogenase Proteins 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 11
- 230000006378 damage Effects 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- 239000006285 cell suspension Substances 0.000 description 10
- 238000011532 immunohistochemical staining Methods 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 208000018737 Parkinson disease Diseases 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 9
- 230000004083 survival effect Effects 0.000 description 9
- 238000001890 transfection Methods 0.000 description 9
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 8
- 210000001159 caudate nucleus Anatomy 0.000 description 8
- 238000004113 cell culture Methods 0.000 description 8
- 210000005064 dopaminergic neuron Anatomy 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 239000000661 sodium alginate Substances 0.000 description 8
- 235000010413 sodium alginate Nutrition 0.000 description 8
- 229940005550 sodium alginate Drugs 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 230000005740 tumor formation Effects 0.000 description 8
- LHQIJBMDNUYRAM-AWFVSMACSA-N D-erythro-biopterin Chemical compound N1=C(N)NC(=O)C2=NC([C@H](O)[C@H](O)C)=CN=C21 LHQIJBMDNUYRAM-AWFVSMACSA-N 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 7
- LHQIJBMDNUYRAM-UHFFFAOYSA-N L-erythro-Biopterin Natural products N1=C(N)NC(=O)C2=NC(C(O)C(O)C)=CN=C21 LHQIJBMDNUYRAM-UHFFFAOYSA-N 0.000 description 7
- 208000012902 Nervous system disease Diseases 0.000 description 7
- 208000025966 Neurological disease Diseases 0.000 description 7
- 238000005538 encapsulation Methods 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 210000001259 mesencephalon Anatomy 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 230000001228 trophic effect Effects 0.000 description 6
- 241000282560 Macaca mulatta Species 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 238000003501 co-culture Methods 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 238000002991 immunohistochemical analysis Methods 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- DUUGKQCEGZLZNO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Chemical compound C1=C(O)C=C2C(CC(=O)O)=CNC2=C1 DUUGKQCEGZLZNO-UHFFFAOYSA-N 0.000 description 4
- 208000024827 Alzheimer disease Diseases 0.000 description 4
- 208000023105 Huntington disease Diseases 0.000 description 4
- 102000013127 Vimentin Human genes 0.000 description 4
- 108010065472 Vimentin Proteins 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 210000001130 astrocyte Anatomy 0.000 description 4
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 230000006735 deficit Effects 0.000 description 4
- 230000003291 dopaminomimetic effect Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000002055 immunohistochemical effect Effects 0.000 description 4
- 238000012744 immunostaining Methods 0.000 description 4
- 239000007943 implant Substances 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 210000003140 lateral ventricle Anatomy 0.000 description 4
- 210000000944 nerve tissue Anatomy 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 230000010412 perfusion Effects 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000008467 tissue growth Effects 0.000 description 4
- 210000005048 vimentin Anatomy 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 108010083674 Myelin Proteins Proteins 0.000 description 3
- 102000006386 Myelin Proteins Human genes 0.000 description 3
- 229930193140 Neomycin Natural products 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 206010052779 Transplant rejections Diseases 0.000 description 3
- 210000002718 aborted fetus Anatomy 0.000 description 3
- 206010000210 abortion Diseases 0.000 description 3
- 231100000176 abortion Toxicity 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 3
- 229960004046 apomorphine Drugs 0.000 description 3
- 210000004227 basal ganglia Anatomy 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 210000002451 diencephalon Anatomy 0.000 description 3
- 210000004002 dopaminergic cell Anatomy 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 229960004502 levodopa Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000003094 microcapsule Substances 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 210000005012 myelin Anatomy 0.000 description 3
- 229960004927 neomycin Drugs 0.000 description 3
- 210000004788 neurological cell Anatomy 0.000 description 3
- 230000014511 neuron projection development Effects 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- 210000004248 oligodendroglia Anatomy 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 210000003523 substantia nigra Anatomy 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000003325 tomography Methods 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- RVWZUOPFHTYIEO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Natural products C1=C(O)C=C2C(C(=O)O)=CNC2=C1 RVWZUOPFHTYIEO-UHFFFAOYSA-N 0.000 description 2
- 239000003310 5-hydroxyindoleacetic acid Substances 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 206010015548 Euthanasia Diseases 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 229910052688 Gadolinium Inorganic materials 0.000 description 2
- 102000053171 Glial Fibrillary Acidic Human genes 0.000 description 2
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 241000233803 Nypa Species 0.000 description 2
- 235000005305 Nypa fruticans Nutrition 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 230000003140 astrocytic effect Effects 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 2
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 238000002650 immunosuppressive therapy Methods 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 210000002241 neurite Anatomy 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 230000007658 neurological function Effects 0.000 description 2
- 230000017511 neuron migration Effects 0.000 description 2
- 230000035771 neuroregeneration Effects 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 210000002243 primary neuron Anatomy 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 229940001089 sinemet Drugs 0.000 description 2
- 210000003625 skull Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 230000003319 supportive effect Effects 0.000 description 2
- 238000011477 surgical intervention Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 208000001608 teratocarcinoma Diseases 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 241000349731 Afzelia bipindensis Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010001541 Akinesia Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 210000003771 C cell Anatomy 0.000 description 1
- 229910004709 CaSi Inorganic materials 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 206010008748 Chorea Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- QTANTQQOYSUMLC-UHFFFAOYSA-O Ethidium cation Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 QTANTQQOYSUMLC-UHFFFAOYSA-O 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 208000015872 Gaucher disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 206010018341 Gliosis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108700021154 Metallothionein 3 Proteins 0.000 description 1
- 102100028708 Metallothionein-3 Human genes 0.000 description 1
- 241001430197 Mollicutes Species 0.000 description 1
- 208000002740 Muscle Rigidity Diseases 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 108010088373 Neurofilament Proteins Proteins 0.000 description 1
- 102000008763 Neurofilament Proteins Human genes 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010067035 Pancrelipase Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 101100111688 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) BNI1 gene Proteins 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 208000022292 Tay-Sachs disease Diseases 0.000 description 1
- NSOXQYCFHDMMGV-UHFFFAOYSA-N Tetrakis(2-hydroxypropyl)ethylenediamine Chemical compound CC(O)CN(CC(C)O)CCN(CC(C)O)CC(C)O NSOXQYCFHDMMGV-UHFFFAOYSA-N 0.000 description 1
- LEBBDRXHHNYZIA-LDUWYPJVSA-N [(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] n-[(z)-1,3-dihydroxyoctadec-4-en-2-yl]carbamate Chemical compound CCCCCCCCCCCCC\C=C/C(O)C(CO)NC(=O)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O LEBBDRXHHNYZIA-LDUWYPJVSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000002927 anti-mitotic effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 208000037875 astrocytosis Diseases 0.000 description 1
- 230000007341 astrogliosis Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 210000002932 cholinergic neuron Anatomy 0.000 description 1
- 208000012601 choreatic disease Diseases 0.000 description 1
- 210000002987 choroid plexus Anatomy 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000002638 denervation Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000001951 dura mater Anatomy 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 229920002457 flexible plastic Polymers 0.000 description 1
- -1 for example Proteins 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 230000006455 idiopathic destruction Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 210000003963 intermediate filament Anatomy 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000005230 lumbar spinal cord Anatomy 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 230000001722 neurochemical effect Effects 0.000 description 1
- 210000005044 neurofilament Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000005015 neuronal process Effects 0.000 description 1
- 230000009689 neuronal regeneration Effects 0.000 description 1
- 230000008906 neuronal response Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 239000003076 neurotropic agent Substances 0.000 description 1
- 230000024121 nodulation Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002330 subarachnoid space Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
- C12Y114/13—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen (1.14.13)
- C12Y114/13041—Tyrosine N-monooxygenase (1.14.13.41)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
- C12Y114/16—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with reduced pteridine as one donor, and incorporation of one atom of oxygen (1.14.16)
- C12Y114/16002—Tyrosine 3-monooxygenase (1.14.16.2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/04—Immortalised cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/108—Plasmid DNA episomal vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Virology (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gynecology & Obstetrics (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/467,958 US5753491A (en) | 1993-04-13 | 1995-06-06 | Use of neuro-derived fetal cell lines for transplantation therapy |
PCT/US1996/008617 WO1996039496A1 (en) | 1995-06-06 | 1996-06-06 | Use of neuro-derived fetal cell lines for transplantation therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
UA61058C2 true UA61058C2 (en) | 2003-11-17 |
Family
ID=23857846
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UA98010030A UA61058C2 (en) | 1995-06-06 | 1996-06-06 | Immortalized human fetal neuro-derived cell line intended for treating parkinsonism, composition suitable for implantation containing immortalized cells |
Country Status (13)
Country | Link |
---|---|
US (1) | US5753491A (de) |
EP (1) | EP0832203A4 (de) |
JP (1) | JPH11506930A (de) |
KR (1) | KR19990022633A (de) |
CN (1) | CN1192781A (de) |
BR (1) | BR9609154A (de) |
CA (1) | CA2221258A1 (de) |
HU (1) | HUP9900899A3 (de) |
IL (1) | IL122337A0 (de) |
NZ (1) | NZ310048A (de) |
RU (1) | RU2234338C2 (de) |
UA (1) | UA61058C2 (de) |
WO (1) | WO1996039496A1 (de) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9518606D0 (en) * | 1995-09-12 | 1995-11-15 | Inst Of Psychiatry | Neural transplantation |
AU7963998A (en) * | 1997-06-13 | 1998-12-30 | University Technology Corporation | Transplantation of immortalized dopamine cells to improve neurological deficits |
US6254865B1 (en) | 1997-06-17 | 2001-07-03 | University Technology Corporation | Method of treating huntington's disease using HNT neurons |
US6835567B1 (en) | 1998-04-14 | 2004-12-28 | Signal Pharmaceuticals, Inc. | PNS cell lines and methods of use therefor |
US20080206206A1 (en) | 1998-05-07 | 2008-08-28 | University Of South Florida | Bone marrow-derived neuronal cells |
WO1999056759A1 (en) | 1998-05-07 | 1999-11-11 | University Of South Florida | Bone marrow cells as a source of neurons for brain and spinal cord repair |
US6787356B1 (en) | 1998-07-24 | 2004-09-07 | The United States Of America As Represented By The Department Of Health And Human Services | Cell expansion system for use in neural transplantation |
US6319905B1 (en) | 1998-12-29 | 2001-11-20 | Cell Genesys, Inc. | Method of controlling L-Dopa production and of treating dopamine deficiency |
AU3751800A (en) * | 1999-03-18 | 2000-10-04 | Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The | Cells, cell populations, and methods of making and using same |
US6303355B1 (en) | 1999-03-22 | 2001-10-16 | Duke University | Method of culturing, cryopreserving and encapsulating pancreatic islet cells |
US6365385B1 (en) | 1999-03-22 | 2002-04-02 | Duke University | Methods of culturing and encapsulating pancreatic islet cells |
GB9907243D0 (en) * | 1999-03-29 | 1999-05-26 | Reneuron Ltd | Therapy |
US20030211085A1 (en) * | 2000-03-16 | 2003-11-13 | Sanberg Paul R. | Cell therapy for chronic stroke |
EP1949904A3 (de) | 1999-04-27 | 2008-08-06 | Layton Bioscience, Inc. | Zelltherapie für chronische Apoplexie |
US6465215B1 (en) | 1999-12-14 | 2002-10-15 | Reneuron Limited | Identification of cells for transplantation |
US6395546B1 (en) | 2000-02-01 | 2002-05-28 | Neurogeneration, Inc. | Generation of dopaminergic neurons from human nervous system stem cells |
EP1263930A4 (de) * | 2000-03-09 | 2004-07-21 | Saneron Ccel Therapeutics Inc | Menschliches nabelschnurblut als quelle für neurales gewebe zur heilung von gehirn und rückenmark |
DE60123937T2 (de) | 2000-04-13 | 2007-06-14 | The Board of Regents, The University of Texas System, Austin | Behandlung von neuro-degenerativen gastrointestinalkrankheiten durch impantation von neuronalen stammzellen und/oder deren nachkommen in gastrointestinalorgane |
US20040092013A1 (en) * | 2001-08-14 | 2004-05-13 | Snyder Evan Y. | Method of treating alzheimer's disease with cell therapy |
EP1561814B1 (de) | 2002-10-22 | 2010-12-22 | Eisai R&D Management Co., Ltd. | Spezifisch in postmitotischen dopamin-produzierenden neuronalen vorläuferzellen exprimiertes gen |
WO2004063356A2 (en) * | 2003-01-13 | 2004-07-29 | Rao Mahendra S | Persistent expression of candidate molecule in proliferating stem and progenitor cells for delivery of therapeutic products |
US20050048041A1 (en) * | 2003-01-13 | 2005-03-03 | Rao Mahendra S. | Persistent expression of candidate molecule in proliferating stem and progenitor cells for delivery of therapeutic products |
CA2574177C (en) | 2004-07-22 | 2019-01-08 | Eisai Co., Ltd. | Lrp4/corin dopaminergic neuron progenitor cell markers |
DE602005002430T2 (de) | 2004-09-30 | 2008-06-19 | Reneuron Ltd., Guildford | Zelllinie |
JP4926966B2 (ja) | 2005-08-18 | 2012-05-09 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ドーパミン産生ニューロン増殖前駆細胞マーカーMsx1/2 |
CN101292031A (zh) | 2005-08-18 | 2008-10-22 | 卫材R&D管理有限公司 | 多巴胺能神经元增殖祖细胞的标记物Nato3 |
US8198081B2 (en) | 2006-04-11 | 2012-06-12 | Eisai R&D Management Co., Ltd. | Dopaminergic neuron progenitor cell marker 187A5 |
US9101570B1 (en) | 2009-02-13 | 2015-08-11 | Endocellutions, Inc. | Adult and neonatal stem cell therapy to treat diabetes through the repair of the gastrointestinal tract |
EP2737057B1 (de) | 2011-07-27 | 2018-10-24 | Kyoto University | Neue marker für dopaminerge neuronale vorläuferzellen |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4707448A (en) * | 1984-10-04 | 1987-11-17 | The United States Of America As Represented By The Department Of Health And Human Services | Immortal line of human fetal glial cells |
US5032407A (en) * | 1987-01-16 | 1991-07-16 | Ohio University Edison Animal Biotechnology Center | Gene transfer using transformed, neodetermined, embryonic cells |
US5202120A (en) * | 1987-09-11 | 1993-04-13 | Case Western Reserve University | Methods of reducing glial scar formation and promoting axon and blood vessel growth and/or regeneration through the use of activated immature astrocytes |
US4892538A (en) * | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
WO1989009816A1 (en) * | 1988-04-12 | 1989-10-19 | Massachusetts Institute Of Technology | Method for manipulation of the cell types of eukaryotes |
EP0445218A4 (en) * | 1988-11-23 | 1991-11-13 | Baylor College Of Medicine | Neural cell transplantation |
US5082670A (en) * | 1988-12-15 | 1992-01-21 | The Regents Of The University Of California | Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system |
US5082676A (en) * | 1989-05-15 | 1992-01-21 | Hag Gf Aktiengesellschaft | Coffee cassette |
AU690548B2 (en) * | 1993-04-13 | 1998-04-30 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Use of neuro-derived fetal cell lines for transplantation therapy |
-
1995
- 1995-06-06 US US08/467,958 patent/US5753491A/en not_active Expired - Fee Related
-
1996
- 1996-06-06 NZ NZ310048A patent/NZ310048A/en unknown
- 1996-06-06 EP EP96918000A patent/EP0832203A4/de not_active Withdrawn
- 1996-06-06 CN CN96196147A patent/CN1192781A/zh active Pending
- 1996-06-06 UA UA98010030A patent/UA61058C2/uk unknown
- 1996-06-06 IL IL12233796A patent/IL122337A0/xx unknown
- 1996-06-06 RU RU98100114/15A patent/RU2234338C2/ru not_active IP Right Cessation
- 1996-06-06 CA CA002221258A patent/CA2221258A1/en not_active Abandoned
- 1996-06-06 KR KR1019970709208A patent/KR19990022633A/ko active IP Right Grant
- 1996-06-06 JP JP9501153A patent/JPH11506930A/ja not_active Withdrawn
- 1996-06-06 WO PCT/US1996/008617 patent/WO1996039496A1/en active IP Right Grant
- 1996-06-06 HU HU9900899A patent/HUP9900899A3/hu not_active Application Discontinuation
- 1996-06-06 BR BR9609154A patent/BR9609154A/pt not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CN1192781A (zh) | 1998-09-09 |
EP0832203A1 (de) | 1998-04-01 |
WO1996039496A1 (en) | 1996-12-12 |
HUP9900899A2 (hu) | 1999-07-28 |
MX9709748A (es) | 1998-07-31 |
JPH11506930A (ja) | 1999-06-22 |
NZ310048A (en) | 1999-09-29 |
IL122337A0 (en) | 1998-04-05 |
BR9609154A (pt) | 1999-06-15 |
CA2221258A1 (en) | 1996-12-12 |
US5753491A (en) | 1998-05-19 |
KR19990022633A (ko) | 1999-03-25 |
RU2234338C2 (ru) | 2004-08-20 |
EP0832203A4 (de) | 2002-07-17 |
HUP9900899A3 (en) | 2001-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA61058C2 (en) | Immortalized human fetal neuro-derived cell line intended for treating parkinsonism, composition suitable for implantation containing immortalized cells | |
EP0696205B1 (de) | Verwendung von neuronalen fötalen zellinien für transplantationstherapie | |
JP4848538B2 (ja) | ヒトcns神経幹細胞の培養 | |
JP2004041757A (ja) | 脳中への細胞の移植のための医薬組成物 | |
CA2407424A1 (en) | Retinal pigment epithelial cell lines with extended life-span and their applications | |
RU2185833C2 (ru) | Нейротрансплантация с использованием плюрипотентных нейроэпителиальных клеток | |
JPH11514877A (ja) | 機能性ランゲルハンス島のインビトロ成長およびそのインビボの使用 | |
US6569421B2 (en) | Treatment of brain damage | |
KR20090055691A (ko) | 인간 제대혈 유래 간엽 줄기세포를 유효성분으로 포함하는,신경전구세포 또는 신경줄기세포의 신경세포로의 분화 및증식 유도용 조성물 | |
CA2128630A1 (en) | A method for transplanting cells into the brain and therapeutic uses therefor | |
AU742824B2 (en) | Use of neuro-derived fetal cell lines for transplantation therapy | |
MXPA97009748A (es) | Uso de lineas celulares fetales neuro-derivadas para terapia de trasplante | |
AU6036396A (en) | Use of neuro-derived fetal cell lines for transplantation therapy | |
NZ334945A (en) | A method of treating neurological disease or disorder by using neuro-derived fetal cell lines in transplantation therapy | |
EP2179031A1 (de) | Aus dem glomus caroticum stammende stammzellen und verwendungen davon | |
EP1231263A1 (de) | Pluripotente O-2A Vorläuferzellen aus der Neurohypophyse | |
US20190010453A1 (en) | Retinal stem cells |